7:40AM Oncolytics Biotech announced publication of preclinical research on synergistic combination of Chemotherapy with Oncolytic Virotherapy (ONCY) 4.35 : The report describes when best to administer taxanes with reovirus to optimize viral delivery to the tumor mass. The researchers demonstrated that this drug combination was superior to either treatment alone, and were able to reproducibly cure nearly half of the treated animals by employing this optimized schedule of paclitaxel/REOLYSIN. "This research supports and further rationalizes the dose schedules currently employed in our ongoing clinical efforts in the phase II and phase III setting," said Matt Coffey, COO of the co.
Market Data 
Markets 
AI
